Compare Cenovus Energy Inc (CVE) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Cassava Sciences Inc — how do they compare? Cenovus Energy Inc trades at $27.59 (market cap $50.90B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Cenovus Energy Inc is far larger — about 966.6× Cassava Sciences Inc's market cap, and Cenovus Energy Inc pays a 2.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CVE | FLNA | |
|---|---|---|
Market Cap | $50.90B | $52.66M |
Sector | Energy | Health |
52-Week High | $31.80 | $4.64 |
52-Week Low | $13.96 | $1.09 |
Enterprise Value | $58.77B | -$33.92M |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $27.61, up 4.58% with strong bullish technical indicators and consistent earnings beats. The stock shows solid fundamentals with a P/E of 15.62, ROE of 14.86%, and improving cash flow projections. Recent news highlights benefits from rising crude prices and operational synergies from MEG Energy acquisition.
CVE presents a compelling investment case with attractive valuation, strong profitability metrics, and positive analyst sentiment (40.74% buy ratings). Key risks include oil price volatility and execution challenges in growth projects. The integrated business model provides resilience across energy cycles.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
